Vis enkel innførsel

dc.contributor.authorSulheim, Einaren_US
dc.contributor.authorMørch, Ýrr Asbjørgen_US
dc.contributor.authorSnipstad, Sofieen_US
dc.contributor.authorBorgos, Sven Even F.en_US
dc.contributor.authorMiletic, Hrvojeen_US
dc.contributor.authorBjerkvig, Rolfen_US
dc.contributor.authorDavies, Catharina de Langeen_US
dc.contributor.authorÅslund, Andreasen_US
dc.date.accessioned2020-04-17T08:20:21Z
dc.date.available2020-04-17T08:20:21Z
dc.date.issued2019-02-07
dc.PublishedSulheim E, Mørch YA, Snipstad S, Borgos SEF, Miletic H, Bjerkvig R, Davies CdeL, Åslund A. Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model. Nanotheranostics. 2019;3(1):103-112eng
dc.identifier.issn2206-7418
dc.identifier.urihttps://hdl.handle.net/1956/21903
dc.description.abstractTreatment of glioblastoma and other diseases in the brain is especially challenging due to the blood-brain barrier, which effectively protects the brain parenchyma. In this study we show for the first time that cabazitaxel, a semi-synthetic derivative of docetaxel can cross the blood-brain barrier and give a significant therapeutic effect in a patient-derived orthotopic model of glioblastoma. We show that the drug crosses the blood-brain barrier more effectively in the tumor than in the healthy brain due to reduced expression of p-glycoprotein efflux pumps in the vasculature of the tumor. Surprisingly, neither ultrasound-mediated blood-brain barrier opening (sonopermeation) nor drug formulation in polymeric nanoparticles could increase either accumulation of the drug in the brain or therapeutic effect. This indicates that for hydrophobic drugs, sonopermeation of the blood brain barrier might not be sufficient to achieve improved drug delivery. Nonetheless, our study shows that cabazitaxel is a promising drug for the treatment of brain tumors.en_US
dc.language.isoengeng
dc.publisherIvyspring International Publishereng
dc.rightsAttribution CC BY-NCeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/eng
dc.subjectcabazitaxeleng
dc.subjectGlioblastomaeng
dc.subjectorthotopic modeleng
dc.subjectsonopermeationeng
dc.titleTherapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Modelen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2020-01-11T18:06:48Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 Ivyspring International Publisher
dc.identifier.doihttps://doi.org/10.7150/ntno.31479
dc.identifier.cristin1750860
dc.source.journalNanotheranostics
dc.relation.projectNorges forskningsråd: 240316
dc.relation.projectRegionalt helseforetak: 900000


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC